List of Posters
Supported by
| Poster Title & Presenting Author |
|---|
| LONG TERM STORAGE OF CRYOPRESERVED AUTOLOGOUS STEM CELL UNITS IN MULTIPLE MYELOMA: SINGLE CENTER STUDY IN TUNISIA Belloumi, Dorra Tunisia E-poster | Abstract |
| HIGH-DOSE MELPHALAN ON DAY 2 VERSUS 1 PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Ben Yaiche, Insaf Tunisia E-poster | Abstract |
| ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET Cerchione, Claudio Italy E-poster | Abstract |
| CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA Cerchione, Claudio Italy E-poster | Abstract |
| REAL-LIFE USE OF POMALIDOMIDE IN SECOND- AND THIRD-LINE (2L AND 3L) THERAPY OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): EMMY STUDY (EPIDEMIOLOGY OF THERAPEUTIC MANAGEMENT OF MULTIPLE MYELOMA IN FRANCE) Decaux, Olivier France E-poster | Abstract |
| WHAT IS THE REAL-LIFE SETTING USE OF LENALIDOMIDE-CORTICOSTEROIDS (LEN-DOUBLET) IN SECOND LINE (2L) IN THE ERA OF TRIPLETS IN MULTIPLE MYELOMA (MM) IN FRANCE? RESULTS FROM EMMY STUDY Decaux, Olivier France E-poster | Abstract |
| TREATMENT OPTIONS FOR FIRST RELAPSE POST-AUTOLOGOUS TRANSPLANT IN THE ERA OF MAINTENANCE THERAPY FOR MULTIPLE MYELOMA: A RETROSPECTIVE REVIEW Duane, Catherine Ireland E-poster | Abstract |
| EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN LENALIDOMIDE-REFRACTORY PATIENTS (PTS) WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY (LOT): CARTITUDE-2 UPDATED RESULTS Einsele, Hermann Germany E-poster | Abstract |
| EFFICACY AND SAFETY OF AUTOLOGOUS TRANSPLANT WITH NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS IN MYELOMA AND LYMPHOMA IN ALGERIA. 10 YEARS’ EXPERIENCE Bekadja, Mohamed Amine Algeria E-poster | Abstract |
| WEEKLY BORTEZOMIB IN INDUCTION CHEMOTHERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT Faulkner, Lucy UK E-poster | Abstract |
| TREATMENT EFFICACY OF PROGRESSION FREE SURVIVAL FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA IN GERIATRIC PATIENTS: A NETWORK META-ANALYSIS Lee, Cho-Hao Taiwan E-poster | Audio | Abstract |
| IMPAIRED BONE METABOLISM IN MULTIPLE MYELOMA ASSESSED BY THE BONE MARKERS SCLEROSTIN AND DICKKOPF-1 Micheva, Ilina Bulgaria E-poster | Abstract |
| POOLED ANALYSIS OF PROGRESSION-FREE SURVIVAL (PFS) ACCORDING TO CYTOGENETIC ABNORMALITY (CA) STATUS IN PATIENTS WITH MULTIPLE MYELOMA (MM) TREATED WITH IXAZOMIB- VS PLACEBO-BASED THERAPY IN THE TOURMALINE PHASE 3 STUDIES Moreau, Philippe France E-poster | Abstract |
| IMPACT OF DOUBLE-HIT GENETICS ON REAL-WORLD OUTCOMES OF MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANPLANTATION (ASCT) – A UK ASCT CENTRE EXPERIENCE Panopoulou, Katerina UK E-poster | Abstract |
| A SINGLE CENTRE STUDY OF PATIENTS WITH MULTIPLE MYELOMA AT A TERTIARY CARE CENTRE IN SRI LANKA Williams, Senani Sri Lanka E-poster | Video | Abstract |
| PROGNOSTIC FACTORS OF IMPACT TO THE COURSE AND OUTCOME OF COVID-19 INFECTION IN PATIENTS WITH MULTIPLE MYELOMA Sretenović, Aleksandra Serbia E-posters | Abstract |
| HIGH-DOSE MELPHALAN ON MULTIPLE MYELOMA-RELATED MUTATIONS, RISK-LEVEL, AND SECONDARY DISEASE BURDEN Sweeney, Nathan USA E-poster | Abstract |
| PROGNOSTIC IMPLICATION OF DEL(13Q) AFTER EXPOSURE TO PESTICIDES IN NEWLY DIAGNOSED MULTIPLE MYELOMA Sweeney, Nathan USA E-poster | Abstract |
| REAL-WORLD OUTCOMES (RWO) FOR STANDARD OF CARE (SOC) TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) Vekemans, Marie-Christiane Belgium E-poster | Abstract |
